During an episode of IASLC’s Lung Cancer Considered podcast, Dr. Singh provided insight into the US agency’s approval process. Here are some highlights. Read more
Interim analysis from ORIENT-31 demonstrates a four-drug regimen may be a reasonable option for patients whose disease has progressed on EGFR TKIs. Read more
Finding precision treatments after molecular testing requires a tool for reviewing actionable mutations. Read more
Without validated biomarkers for anti-angiogenesis therapy, VEGF inhibitors are increasingly being investigated. Read more
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time. Read more
Liquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more
The UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution. Read more
The onboarding required to participate in a clinical trial is extensive. The offboarding, however, can feel like abandonment for some patients. Read more
Study tests combination of taxanes with an angiogenesis inhibitor in search for better outcomes for patients with advanced KRAS-mutated NSCLC. Read more
During an interview with ILCN, Drs. Paul Paik and Jonathan Reiss discuss the implications of KEAP1 and NFE2L2 mutations in NSCLC. Read more